Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2576-2584

  Deplaine, Guillaume ^a,b,c   Lavazec, Catherine ^a,b   Bischoff, Emmanuel ^a,b   Natalang, Onguma ^a,b,d   Perrot, Sylvie ^a,b   Guillotte Blisnick, Micheline ^a,b   Coppée, Jean Yves ^a   Pradines, Bruno ^b   Mercereau Puijalon, Odile ^a,b   David, Peter H ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; MESSENGER RNA; PART PROTEIN; PROTOZOAL PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; GENE IDENTIFICATION; GROWTH INHIBITION; HIDDEN MARKOV MODEL; IMMUNODETECTION; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; SURVIVAL; TRANSGENIC ORGANISM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIMALARIALS; ARTEMISININS; DRUG TOLERANCE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 79956294275     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01409-10     Document Type: Article

References (55)

1. Adams, P. A., P. A. Berman, T. J. Egan, P. J. Marsh, and J. Silver. 1996. The iron environment in heme and heme-antimalarial complexes of pharmacological interest. J. Inorg. Biochem. 63:69-77.
2. Asawamahasakda, W., I. Ittarat, Y. M. Pu, H. Ziffer, and S. R. Meshnick. 1994. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. 38:1854-1858.
3. Batty, K. T., K. F. Ilett, T. Davis, and M. E. Davis. 1996. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J. Pharm. Pharmacol. 48:22-26.
4. Bora, H., et al. 2011. Plasmodium vivax tryptophan-rich antigen PvTRAg33.5 contains alpha helical structure and multidomain architecture. PLoS One 6:e16294.
5. Bork, P., and M. Sudol. 1994. The WW domain: a signalling site in dystrophin? Trends Biochem. Sci. 19:531-533.
6. Briolant, S., et al. 2010. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob. Agents Chemother. 54:3537-3544.
7. Chan, D. I., E. J. Prenner, and H. J. Vogel. 2006. Tryptophan- and argininerich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 1758:1184-1202.
8. Chavchich, M., et al. 2010. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob. Agents Chemother. 54:2455-2464.
9. Crabb, B. S., T. Triglia, J. G. Waterkeyn, and A. F. Cowman. 1997. Stable transgene expression in Plasmodium falciparum. Mol. Biochem. Parasitol. 90:131-144.
10. de Castro, F. A., et al. 1996. Identification of a family of Rab G-proteins in Plasmodium falciparum and a detailed characterisation of pfrab6. Mol. Biochem. Parasitol. 80:77-88.
11. Deitsch, K., C. Driskill, and T. Wellems. 2001. Transformation of malaria parasites by the spontaneous uptake and expression of DNA from human erythrocytes. Nucleic Acids Res. 29:850-853. (Pubitemid 32124398)
12. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
13. Ding, X. C., H. P. Beck, and G. Raso. 2011. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol. 27:73-81.
14. Dondorp, A. M., et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
15. Dondorp, A. M., et al. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272-280.
16. Duraisingh, M. T., T. Triglia, and A. F. Cowman. 2002. Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination. Int. J. Parasitol. 32:81-89.
17. Eckstein-Ludwig, U., et al. 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961. (Pubitemid 37051688)
18. Fandeur, T., S. Bonnefoy, and O. Mercereau-Puijalon. 1991. In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are genetically unrelated. Mol. Biochem. Parasitol. 47:167-178.
19. Foth, B. J., N. Zhang, S. Mok, P. R. Preiser, and Z. Bozdech. 2008. Quantitative protein expression profiling reveals extensive post-transcriptional regulation and post-translational modifications in schizont-stage malaria parasites. Genome Biol. 9:R177.
20. Ginsburg, H., S. Kutner, M. Krugliak, and Z. I. Cabantchik. 1985. Characterization of permeation pathways appearing in the host membrane of Plasmodium falciparum infected red blood cells. Mol. Biochem. Parasitol. 14: 313-322.
21. Golenser, J., J. H. Waknine, M. Krugliak, N. H. Hunt, and G. E. Grau. 2006. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36:1427-1441.
22. Hartwig, C. L., et al. 2009. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide- dependent. Biochem. Pharmacol. 77:322-336.
23. Haynes, R. K. 2006. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr. Top. Med. Chem. 6:509-537.
24. Haynes, R. K., et al. 2007. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem 2:1448-1463.
25. Hoshen, M. B., K. Na-Bangchang, W. D. Stein, and H. Ginsburg. 2000. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of "dormancy", a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121: 237-246.
26. Hu, G., et al. 2010. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat. Biotechnol. 28:91-98.
27. Jambou, R., et al. 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960-1963. (Pubitemid 41713986)
28. Kanei-Ishii, C., et al. 1990. The tryptophan cluster: a hypothetical structure of the DNA-binding domain of the myb protooncogene product. J. Biol. Chem. 265:19990-19995.
29. Kay, B. K., M. P. Williamson, and M. Sudol. 2000. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14:231-241. (Pubitemid 30086060)
30. Klein-Seetharaman, J., et al. 2002. Long-range interactions within a non native protein. Science 295:1719-1722. (Pubitemid 34202908)
31. Krishna, S., L. Bustamante, R. K. Haynes, and H. M. Staines. 2008. Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 29:520-527.
32. Krishna, S., S. Pulcini, F. Fatih, and H. Staines. 2010. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends Parasitol. 26: 517-523.
33. Krishna, S., C. J. Woodrow, H. M. Staines, R. K. Haynes, and O. Mercereau- Puijalon. 2006. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol. Med. 12:200-205.
34. Lavazec, C., S. Sanyal, and T. J. Templeton. 2006. Hypervariability within the Rifin, Stevor and Pfmc-2TM superfamilies in Plasmodium falciparum. Nucleic Acids Res. 34:6696-6707.
35. Maude, R. J., et al. 2009. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar. J. 8:31.
36. Medhi, B., S. Patyar, R. S. Rao, D. S. P. Byrav, and A. Prakash. 2009. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 84:323-332.
37. Natalang, O., et al. 2008. Dynamic RNA profiling in Plasmodium falciparum synchronized blood stages exposed to lethal doses of artesunate. BMC Genomics 9:388.
38. Newton, P. N., et al. 2006. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur. J. Clin. Pharmacol. 62:1003-1009.
39. Noedl, H., D. Socheat, and W. Satimai. 2009. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361:540-541.
40. Ntumngia, F. B., N. Bahamontes-Rosa, and J. F. Kun. 2005. Genes coding for tryptophan-rich proteins are transcribed throughout the asexual cycle of Plasmodium falciparum. Parasitol. Res. 96:347-353.
41. Palacpac, N. M., Y. Hiramine, F. Mi-ichi, et al. 2004. Developmental-stage-specific triacylglycerol biosynthesis, degradation and trafficking as lipid bodies in Plasmodium falciparum-infected erythrocytes. J. Cell Sci. 117:1469-1480.
42. Pasvol, G., R. J. Wilson, M. E. Smalley, and J. Brown. 1978. Separation of viable schizont-infected red cells of Plasmodium falciparum from human blood. Ann. Trop. Med. Parasitol. 72:87-88.
43. Sanchez, C. P., A. Dave, W. D. Stein, and M. Lanzer. 2010. Transporters as mediators of drug resistance in Plasmodium falciparum. Int. J. Parasitol. 40:1109-1118.
44. Sidhu, A. B., et al. 2006. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194:528-535.
45. Sudol, M., and T. Hunter. 2000. NeW wrinkles for an old domain. Cell 103:1001-1004. (Pubitemid 32037388)
46. Teja-Isavadharm, P., et al. 1996. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br. J. Clin. Pharmacol. 42:599-604.
47. Teuscher, F., et al. 2010. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202:1362-1368.
48. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
49. Wang, J., et al. 2010. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5:e9582.
50. Winter, G., et al. 2005. SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites and infected erythrocytes. J. Exp. Med. 201:1853-1863.
51. Witkowski, B., et al. 2010. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 54:1872-1877.
52. Wu, Y., C. D. Sifri, H. H. Lei, X. Z. Su, and T. E. Wellems. 1995. Transfection of Plasmodium falciparum within human red blood cells. Proc. Natl. Acad. Sci. U. S. A. 92:973-977.
53. Yang, H., et al. 2003. Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans. R. Soc. Trop. Med. Hyg. 97:226-228.
54. Yau, W. M., W. C. Wimley, K. Gawrisch, and S. H. White. 1998. The preference of tryptophan for membrane interfaces. Biochemistry 37:14713-14718.
55. Zacharias, N., and D. A. Dougherty. 2002. Cation-pi interactions in ligand recognition and catalysis. Trends Pharmacol. Sci. 23:281-287.